Incidental detection of medullary thyroid carcinoma by 68Ga-DOTATATE PET/CT in a patient with neuroendocrine tumor liver metastases

摘要

⁶⁸Ga-DOTATATE, a positron-emitting somatostatin analogue, has been approved by the Food and Drug Administration for imaging neuroendocrine tumors (NET). The presence of a second primary malignancy is common in NETs; however, synchronous primary malignancy in the thyroid has rarely been reported. The value of ⁶⁸Ga-DOTATATE in medullary thyroid cancer is being investigated and is currently recommended for use when treatment with somatostatin analogues is an option. We present a 55-year-old man with abdominal pain associated with well differentiated NET liver metastases and incidental medullary thyroid carcinoma demonstrated on a ⁶⁸Ga-DOTATATE PET/CT.